-
1
-
-
38149048638
-
Reduction of proteinuria by rosiglitazone in non-diabetic renal disease
-
Kincaid-Smith P, Fairley KF, Farish S, Best JD, Proietto J. Reduction of proteinuria by rosiglitazone in non-diabetic renal disease. Nephrology (Carlton) 2008;13(1):58-62.
-
(2008)
Nephrology (Carlton)
, vol.13
, Issue.1
, pp. 58-62
-
-
Kincaid-Smith, P.1
Fairley, K.F.2
Farish, S.3
Best, J.D.4
Proietto, J.5
-
2
-
-
38149021580
-
Antiproteinuric and antiinflammatory effects of thiazolidinedione
-
Szeto CC, Li PK. Antiproteinuric and antiinflammatory effects of thiazolidinedione. Nephrology (Carlton) 2008;13(1):53-7.
-
(2008)
Nephrology (Carlton)
, vol.13
, Issue.1
, pp. 53-57
-
-
Szeto, C.C.1
Li, P.K.2
-
3
-
-
7044271016
-
Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease
-
Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17(5):365-70.
-
(2004)
Semin Dial
, vol.17
, Issue.5
, pp. 365-370
-
-
Snyder, R.W.1
Berns, J.S.2
-
4
-
-
3242783305
-
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity
-
Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44(2):215-22.
-
(2004)
J. Cardiovasc. Pharmacol.
, vol.44
, Issue.2
, pp. 215-222
-
-
Yosefy, C.1
Magen, E.2
Kiselevich, A.3
Priluk, R.4
London, D.5
Volchek, L.6
-
5
-
-
14744285718
-
The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension
-
Sarafidis PA, Lasaridis AN, Nilsson PM, Hitoglou-Makedou AD, Pagkalos EM, Yovos JG, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension. Am J Hypertens 2005;18(2 Pt 1):227-34.
-
(2005)
Am. J. Hypertens
, vol.18
, Issue.1-2 PT.
, pp. 227-234
-
-
Sarafidis, P.A.1
Lasaridis, A.N.2
Nilsson, P.M.3
Hitoglou-Makedou, A.D.4
Pagkalos, E.M.5
Yovos, J.G.6
-
6
-
-
0036116895
-
Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat
-
Yamashita H, Nagai Y, Takamura T, Nohara E, Kobayashi K. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat. Metabolism 2002;51(4):403-8.
-
(2002)
Metabolism
, vol.51
, Issue.4
, pp. 403-408
-
-
Yamashita, H.1
Nagai, Y.2
Takamura, T.3
Nohara, E.4
Kobayashi, K.5
-
7
-
-
6944250878
-
Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice
-
Tanimoto M, Fan Q, Gohda T, Shike T, Makita Y, Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004;53(11):1473-9.
-
(2004)
Metabolism
, vol.53
, Issue.11
, pp. 1473-1479
-
-
Tanimoto, M.1
Fan, Q.2
Gohda, T.3
Shike, T.4
Makita, Y.5
Tomino, Y.6
-
8
-
-
0034949794
-
Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria
-
DOI 10.1046/j.1464-5491.2001.00463.x
-
Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara L, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001;18(4):308-13. (Pubitemid 32579361)
-
(2001)
Diabetic Medicine
, vol.18
, Issue.4
, pp. 308-313
-
-
Nakamura, T.1
Ushiyama, C.2
Suzuki, S.3
Shimada, N.4
Sekizuka, K.5
Ebihara, L.6
Koide, H.7
-
9
-
-
0037258604
-
Rosiglitazone reduces urinary albumin excretion in type II diabetes
-
Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17(1):7-12.
-
(2003)
J. Hum Hypertens
, vol.17
, Issue.1
, pp. 7-12
-
-
Bakris, G.1
Viberti, G.2
Weston, W.M.3
Heise, M.4
Porter, L.E.5
Freed, M.I.6
-
10
-
-
0033387870
-
Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney
-
Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277(6 Pt 2): F966-F973.
-
(1999)
Am. J. Physiol.
, vol.277
, Issue.2-6 PT.
-
-
Yang, T.1
Michele, D.E.2
Park, J.3
Smart, A.M.4
Lin, Z.5
Brosius, F.C.6
-
11
-
-
0037883037
-
Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients
-
Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003;52(8):1943-50.
-
(2003)
Diabetes
, vol.52
, Issue.8
, pp. 1943-1950
-
-
Miyazaki, Y.1
He, H.2
Mandarino, L.J.3
DeFronzo, R.A.4
-
12
-
-
0031819895
-
Urinary excretion rate is the best individual predictor to ESRF in non-diabetic chronic nephropathies
-
Ruggenenti P, Perna A, Mosconi L, PisoniI R, Remuzzi G. Urinary excretion rate is the best individual predictor to ESRF in non-diabetic chronic nephropathies. Kidney Int 1998;53(5):1209-16.
-
(1998)
Kidney Int.
, vol.53
, Issue.5
, pp. 1209-1216
-
-
Ruggenenti, P.1
Perna, A.2
Mosconi, L.3
PisoniI, R.4
Remuzzi, G.5
-
13
-
-
0035912555
-
Progression, remission, regression of chronic renal diseases
-
Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357(9268):1601-8.
-
(2001)
Lancet
, vol.357
, Issue.9268
, pp. 1601-1608
-
-
Ruggenenti, P.1
Schieppati, A.2
Remuzzi, G.3
-
14
-
-
0035046542
-
Peroxisome proliferator-activated receptorgamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats
-
Ma LJ, Marcantoni C, Linton MF, Fazio S, Fogo AB. Peroxisome proliferator-activated receptorgamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int 2001;59(5):1899-910.
-
(2001)
Kidney Int.
, vol.59
, Issue.5
, pp. 1899-1910
-
-
Ma, L.J.1
Marcantoni, C.2
Linton, M.F.3
Fazio, S.4
Fogo, A.B.5
-
15
-
-
0037362398
-
Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR) gamma activators
-
Haraguchi K, Shimura H, Onaya T. Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR) gamma activators. Clin Exp Nephrol 2003;7(1):27-32.
-
(2003)
Clin. Exp. Nephrol.
, vol.7
, Issue.1
, pp. 27-32
-
-
Haraguchi, K.1
Shimura, H.2
Onaya, T.3
|